SR-123781A

DB05361InvestigationalSmall molecule

SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

Mechanism: SR123781A is a synthetic hexadecasaccharide comprising an antithrombin (AT) binding domain, a thrombin binding domain, and a neutral methylated hexasaccharide sequence, was obtained from glucose through a convergent synthesis. SR123781A showed high affinity for human AT and was a potent catalyst of its inhibitory effect with regard to factor Xa and thrombin.
Curator reviewed
Primary indication: Investigated for use/treatment in cardiovascular disorders, thrombosis, and venous thromboembolism.Curator reviewed
Formula / weight: C₁₂₇H₂₀₁Na₃₇O₁₃₄S₁₇ · 5267.5 g/mol (avg)
Code names: SANORG-123781 · SR-123781 · SR-123781A

Resolves to

Compound

UNIIV952P6826MCAS232602-93-6

Structure

InChIKeyRRHHPXJSGSYSHW-ZURHXDBDSA-ASMILES

[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[H][C@@]1(O[C@@H]2O[C@H](COC)[C@@]([H])(O[C@@H]3O[C@H](COC)[C@@]([H])(O[C@@H]4O[C@H](COC)[C@@]([H])(O[C@H]5O[C@H](COS([O-])(=O)=O)[C@@]([H])(O[C@@H]6O[C@H](COS([O-])(=O)=O)[C@@]([H])(O[C@H]7O[C@H](COS([O-])(=O)=O)[C@@]([H])(O[C@H]8O[C@H](COS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@H]8OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@H]7OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@H]6OS([O-])(=O)=O)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OC)[C@H]3OC)[C@H](OC)[C@H]2OC)[C@@H](COC)O[C@H](O[C@]2([H])[C@@H](COC)O[C@@H](O[C@]3([H])[C@@H](COC)O[C@H](O[C@]4([H])[C@@H](COC)O[C@@H](O[C@@]5([H])[C@@H](COS([O-])(=O)=O)O[C@H](O[C@@]6([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]7([H])[C@@H](COS([O-])(=O)=O)O[C@H](O[C@@]8([H])[C@H](OC)[C@H](OC)[C@H](O[C@]9([H])[C@@H](COS([O-])(=O)=O)O[C@H](OC)[C@@H](OS([O-])(=O)=O)[C@H]9OC)O[C@H]8C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]7OS([O-])(=O)=O)O[C@H]6C([O-])=O)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OC)[C@H]3OC)[C@H](OC)[C@H]2OC)[C@H](OC)[C@H]1OC

Targets

P00734F2 P00742F10P01008SERPINC1P25116F2R

What you can answer from here — as of September 24, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

642Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with SR-123781A, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account